This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Asia: Oligonucleotide & Peptide Therapeutics
24-26 Feb, 2026
Grand Nikko Tokyo DaibaTokyo
Book Now
Menu
Book Now

Dr. Tomoya Takenaka, PhD
Principal Scientist, Drug Product and Device Development at Takeda Pharmaceutical Company
Speaker

Profile

Dr. Tomoya Takenaka has over 15 years of experience in CMC formulation development at Takeda Pharmaceutical Company, with extensive involvement in injectable drug product development from preclinical stages to NDA/BLA submission. He holds a Ph.D. in Science from Osaka Prefecture University, focusing on exosome research, and has an academic background in Material Engineering from the University of Tokyo, where he studied polymeric micelle-based drug delivery systems.

Agenda Sessions

  • Formulation Innovations for Future Oligonucleotide Therapies: Insights Inspired by Biologics

    , 11:00am
    View Session

At this event

Prev
Next
Hideki Tomioka, PhD
Director of the Board and CSO
FunPep Co., Ltd.

See Tomoya at TIDES Asia: Oligonucleotide & Peptide Therapeutics

Book Now